{"entity":{"id":"nct06782685","kind":"trial","name":"Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV","aka":[],"tldr":"A phase 1/2 trial of cAPOX (capecitabine, oxaliplatin), bevacizumab, fluorouracil (5-FU) and leucovorin (folinic acid) in pancreatic cancer, run by Dai, Guanghai, now recruiting.","summary":"Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV is a phase 1/2, randomised interventional study registered as NCT06782685 by Dai, Guanghai, with a registry enrolment figure of 138 participants, started 2024-06-23 and due to reach its primary completion in 2026-07. Interventions recorded: Irinotecan liposoma; oxaliplatin; bevacizumab; 5-FU; LV; Irinotecan Liposomal; Irinotecan Liposomal; Oxaliplatin. Conditions listed: Advanced Pancreatic Cancer (Part 1). Primary outcome: To explore the optimal dose combination of irinotecan liposomes plus oxaliplatin in the regimen of irinotecan liposomes plus oxaliplatin in bevacizumab. Pancreatic eligibility wording from the registry: \"Patients with pancreatic cancer diagnosed by histopathology or cytology;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06782685","url":"https://clinicaltrials.gov/study/NCT06782685"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["capox","bevacizumab","fluorouracil","leucovorin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06782685","phase":"1/2","setting":"Liposomal Irinotecan in Combination With Oxaliplatin and Bevacizumab Versus Liposomal Irinotecan in Combination With 5-FU/LV for the Second-line Treatment of Advanced Pancreatic Cancer","sponsor":"Dai, Guanghai","enrolled":138,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06782685/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"leucovorin","kind":"drug","name":"Leucovorin (folinic acid)","route":"/drugs/leucovorin/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}